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Introduction
Major Depressive Disorder (MDD) is ranked as the second leading contributor to the global disease burden in terms of the years lived with disability (1) . The narrow sense heritability of MDD has been estimated to be approximately 37% by twin studies (2) , suggesting a substantial contribution from genetic factors. In efforts to identify specific genetic risk factors for MDD, family-based linkage studies have identified several significant peaks in certain families, but the findings have been inconsistent (3) . GWAS studies of unrelated participants have successfully identified hundreds of loci associated with other psychiatric disorders(4), but for MDD, only four genome-wide significant and replicable loci have been identified by two large GWAS studies, one on a refined MDD phenotype for Chinese Women and one on self-report-based depression using less intensive phenotyping in a much larger European sample(5-7).
Several factors may be responsible for the comparatively sparse GWAS results in MDD. First, MDD is likely to have a highly polygenic genetic architecture where the disease risk is conferred by many causal variants of small effect (8, 9) . Combined with the high prevalence of MDD (10) and the possible incomplete LD between genotyped SNPs and causal SNPs, single-SNP based genome-wide association tests may have insufficient power to detect individual causal variants (11) . Second, clinical heterogeneity has been shown in MDD between populations (6, 12) , and this may lead to difficulties in identifying causal variants across cohorts (13) . Whilst GWAS sample sizes for MDD are increasing and efforts to refine MDD phenotype are in progress (5, 7) , alternative methodologies for detecting the signal arising from causal variants within and across families may also be productive.
Regional heritability mapping (RHM) is a method used to identify small genomic regions accounting for a significant proportion of the phenotypic variance in a trait of interest (14) . In contrast to single-SNP based tests, RHM integrates effects from multiple SNPs by utilizing a regional genetic relationship matrix estimated from SNPs within a region. The matrix is constructed for each region defined by a sliding window across the genome, and is then used to estimate the variance explained by the variants within the region in a linear mixed model (14) . The major advantage of RHM is that the regional genetic relationship matrices not only tag the effect of genotyped variants, but also measure the effect of un-genotyped and rare variants, including those associated with the SNPs but with individual effects too small to be detected by GWAS (14, 15) . Previous studies have shown that RHM has greater power to detect rare variants and multiple alleles in regions where GWASs provided null findings (15) (16) (17) . In 2014, Shirali .,et.al developed a haplotype-block-based heritability mapping (HRHM) method as an improved version of RHM. HRHM utilizes haplotype blocks as the unit of mapping therefore the identified blocks have less complex local LD structures (18) .
In this study, we applied HRHM to a homogenous sample of approximately 20K Scottish participants containing both closely-and distantly-related subjects with genome-wide genotyping data and a standardised structured clinical MDD diagnosis (19) . We sought to identify genomic regions conferring risk for MDD, which were then further explored using single-SNP-and haplotype-based association tests.
We then examined the functional effects of the MDD-associated SNPs within the identified block. Finally, replication analyses were performed in independent samples for both the regional heritability and SNP association results.
Methods and Materials
The Tayside Research Ethics Committee (reference 05/S1401/89) provided ethical approval for the study. Participants all gave written consent, after having an opportunity to discuss the project, and before any data or samples were collected.
Datasets
Discovery sample: Generation Scotland: The Scottish Family Health Study (GS:SFHS) contains 21,387 subjects (N male =8,772, N female =12,615; Age mean =47.2(SD=15.1)), who were recruited from the registers of collaborating general practices in Glasgow, Tayside, Ayrshire, Arran and Northeast regions of Scotland. At least one first-degree relative aged 18 or over was required to be identified for each participant (19, 20) . A structured clinical interview was used for the diagnosis of lifetime DSM-IV mood disorders (SCID) (21, 22) . Details of MDD diagnosis, genotyping, quality control (QC) and imputation methods are described in the Supplement. In total 561,125 genotyped and 8,642,105 post-imputation autosomal SNPs passed QC criteria were available for 19,896 participants (2,659 MDD cases and 17,237 controls) for subsequent analyses.
Replication sample 1: UK Biobank
Data used in this study were provided as part of UK Biobank project reference #4844.
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Details for genotyping, quality control, imputation and phenotyping are described in the Supplement. In brief, genotyping data was available for 152,729 UK Biobank participants recruited in United kingdom (23 The Psychiatric Genomics Consortium provided individual genotypes (best guess) of imputed SNPs for participants from 22 cohorts in PGC2-MDD (Table s1 ). All cases met DSM-IV criteria for life MDD, the majority of them were ascertained clinically.
Most control samples were screened and participants with lifetime MDD were removed (Table s1 ). Details for genotyping, quality control, imputation and phenotyping are described in the Supplement. After quality control and removing subjects overlapped with GS:SFHS and UK Biobank dataset, 32,554 subjects of European ancestry (13,261 cases and 19,293 controls) were used in downstream analysis. Consistent with earlier work (25, 26) , we grouped the 22 cohorts into 7 groups based on the country of ancestor information for regional heritability analysis (Table s1 ). Okbay et.al (2016) carried out a GWAS meta-analysis (N = 180,866) on three samples using depressive symptoms as the trait of interest (27) . The ascertained MDD diagnosis information was available for two samples (PGC1-MDD(N cases = 9,240, Nc ontrols = 9,519) and the Resource for Genetic Epidemiology Research on Aging (GERA, N cases = 7,231, N controls = 49,316)) (27) . For the third sample (UK Biobank (N = 105,739)), a continuous phenotype measuring the severity of depressive symptom had been created and used in the meta-analysis (27) . Whilst this sample overlapped with the PGC2-MDD and UK Biobank samples, it provided results based upon a nondiagnostic quantitative measure of depressive symptoms and involved another large cohort, GERA (27) .
Genome-wide haplotype-block-based Regional Heritability Mapping (HRHM)
Regional heritability mapping (RHM) is a method for detecting localized genomic regions where genetic variants contribute significantly to the variation of phenotype of interest (14) . As an improved version of RHM, HRHM divides the genome into haplotype-blocks, based on the recombination hotspots in the genome (18) . Details of HRHM are described in the Supplement. In brief, in GS:SFHS the genotyped SNPs were mapped to 49,637 haplotype-blocks across the genome and the regional heritability was estimated and tested for each of the haplotype-blocks. A standard 'two-GRM' model incorporates two genomic relationship matrices (GRM); a regional genomic relationship matrix (rGRM) estimated from SNPs in the haplotype block and a complement genomic relationship matrix (cGRM) estimated from all SNPs that are not included in in the haplotype block. These GRMs were jointly fitted as random effects in LMM. Covariates fitted as fixed effects include age, age 2 , sex, 20 principal components. A Log likelihood ratio test (LRT) is applied to test the significance of random effect represented in rGRM by comparing a model with both cGRM and an rGRM fitted against a model including the cGRM but without an rGRM fitted. The genome-wide significance threshold for P values from LRT is 1.01x10
). This two-GRM model, while providing an unbiased estimate of regional heritability, was highly computationally demanding. To improve the calculation efficiency, a pre-adjustment strategy was applied in the genome-wide HRHM (Supplement). For haplotype-blocks that exceeded the genome-wide significant threshold, we re-tested the block using the two-GRM model to provide an accurate estimation of regional heritability in the target block. All the analyses were performed in REACTA (14, 28) . According to the GCTA-GREML Power Calculator, this study is well-powered for the GREML-based SNP heritability analysis (99.88%) (29) .
Localized association tests for the significant haplotype block identified by HRHM in GS:SFHS
HRHM identified a significant block chr20:42555671-42579473, we performed a series of association tests to localize the association signals within this block in GS:SFHS.
1) Single-SNP-based association test for common SNPs within the identified haplotype-block.
Association tests were performed on genotyped and imputed common SNPs located in the significant haplotype-block chr20:42555671-42579473 using GCTA-MLMA (linear mixed model based association analysis) (30) . The SNP effect was tested as a fixed effect, other covariates included age, age 2 , sex and 20 PCs. To prevent the estimates of SNP effects from being confounded by the polygenic component and family structure, cGRM and cGRM kin were fitted simultaneously as random effects in the model (31) . cGRM (complement-snp-set GRM) was the genomic relationship created matrix using all of the genotyped SNPs excluding the SNPs in the hit block;
cGRM kin was the kinship relationship matrix (representing pedigree-associated genetic variation). cGRM kin was created by setting elements in cGRM that were less than or equal to 0.05 to 0(31). The estimated fixed effect (on the linear scale) was transformed to logit and liability scale using Taylor series approximation (32) .
Bonferroni multiple-testing-correction was performed for the P values for each SNP.
2) Single-haplotype-based association test
Single-haplotype-based association tests were performed for the common haplotypes (Frequency≥0.01) derived from the nine genotyped common SNPs located in the significant haplotype-block chr20:42555671-42579473 using GCTA-MLMA(30) for the full dataset and an unrelated dataset, and using famLBL(33) for a subset consisting of case-parent trios in GS:SFHS. Details of single-haplotype-based association test are described in the Supplement. 
Functional effects of MDD-associated-SNPs in the significant block

Replication analysis
Regional heritability in the significant block identified in GS:SFHS Individual genotypes in UKbiobank and PGC2-MDD(22 cohorts) were used to estimate the regional heritability of the target haplotype block in the two samples. The two-GRM model (rGRM+cGRM) was applied to provide accurate estimates. For PGC2-MDD, the regional heritability was estimated for each of the 7 groups defined based on country of ancestor (Table s1) ) and the regional heritability ( ) was estimated to be 0.008(0.006).
The regional heritability of this block was more significant in females MDD ( =0.009, se=0.007, P lrt =5.64x10 -5 , N case =1,893, N control =9,818) than in males MDD ( 0.003, se=0.004, P lrt =0.02, N case =765, N control =7,420).
We further performed a series of association tests to disentangle the signal detected by HRHM in the significant block. Using the single-SNP-based association test, five of the nine genotyped common SNPs within the hit block were significantly associated with MDD (Table 1, s2 ). The five significant SNPs were in high linkage disequilibrium (LD) with each other ( Figure 1D ) and their minor alleles showed a consistent negative effect on the risk of MDD with the odds ratio ranging from 0.785 to 0.833 (Table 1) . Haplotype-based association tests for haplotypes derived from the nine SNPs showed that two out of the seven common haplotypes (frequency ≥ 0.01)
were associated with MDD. One of these haplotypes contains the minor (protective) alleles of the five single-SNP-level significant SNPs and one contains the major (risk)
alleles. The size and the direction of the effects of the two haplotypes were consistent with that estimated from the single-SNP based tests (odds ratio: 0.792 for the protective haplotype and 1.232 for the risk haplotype) ( Table 2 ). Additional association tests on sub datasets (unrelated and case-parents-trio) showed that the risk haplotype was significantly associated with MDD in the unrelated dataset (Table s3) , whereas the protective haplotype was significant in case-parents-trio dataset (Table   s4 ).
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The significant block overlapped with an enhancer active in multi-tissues and cell lines including astrocytes ( Figure 2A ) (37) , and multiple alternative transcription start sites (TSSs) including a TSS primarily expressed in thalamus (the TSS labeled as 'p3@TOX2' in Figure 2A ) (37) , suggesting a potential regulatory role. To link the association signal from single variants with the potentially functional effects of those variants on disease-relevant biological processes, we identified 38 imputed SNPs in the target block significantly associated with MDD (Table s5) (Table s10 ).
cg24403644 is located in a cluster of TSSs in TOX2 (Figure 2 ) and shows differential methylation between human fetal and postnatal lifetime in frontal cortex and during the fetal brain development (38, 39) . Among significant SNPs in the cis-eQTL and cismeQTL analyses, rs79645278 located in the peak of active enhancer (in astrocytes and other cell lines), and was predicted to be 'likely to affect TF binding' (2b) in RegulomeDB, having a GWAVA-TSS score of 0.5 and a GERP-score of 2.31( Figure   2A ,B,C, Table s6 ).
The regional heritability detected in the hit block was replicated in the UK-Ireland group in PGC2-MDD with nominal significance (P lrt =0.049, =0.001,se=0.001),
whilst it was not significant in other groups in PGC2-MDD and UK Biobank (Table   s11 ). The single-SNP-based association test for the five significant SNPs (genotyped) in this block identified in GS:SFHS showed that all five were replicated in the DS sample; all five were also replicated in the UK-Ireland group in PGC2-MDD (Table 1 .
Results for individual cohorts were shown in Table s12 and Figure s1 ), but not in other PGC2-MDD groups or in the meta-analysed combined PGC2-MDD sample (Table s13) ; none of the five SNPs were replicated in the UK Biobank sample but all showed the same consistent direction of effect with that reported in the discovery sample (Table 1, Figure s1 ). Meta-analysis using all independent UK-Ireland replication samples (UK Biobank + 4 cohorts in PGC2-MDD-UK_Ireland) showed that all of the five SNPs reached nominal significance (Table s13 , consistent sign with GS:SFHS as shown in Figure 3 , using SNP rs6093898 as an example.
Discussion
The current study used a combination of genome-wide haplotype-block-based blocks were used as the unit of mapping, the identified locus has a less complex LD structure ( Figure 1D ), which will benefit the downstream identification of candidate variants.
To date, published GWASs have mapped associated variants to very few genes for MDD (LHPP, SIRT1, TMEM161B-MEF2C and NEGR1) (5, 7) . In this study, the identified haplotype block was located in gene TOX2 (TOX high mobility group box family member 2, also known as GCX1), indicating a new candidate gene for MDD.
TOX2 is a putative transcriptional activator involved in the hypothalamo-pituitarygonadal system (40) , and is located in a large genomic region which has been previously reported as associated with depression symptoms in psychotic illness (41, 42) . The same locus has also been weakly-associated with conduct disorder in a previous study (43) . Using available databases, we found that convergent evidence from TSS by Fantom5 annotation (Figure 2A ), histone modification markers and Dnase peaks representing active enhancers by ENCODE annotation (Figure 2A) , and transcription factor binding prediction by RegulomeDB (Table s6) Table   s10 ) (12) . Notably, UK-Ireland which shows the most consistent replication results are from the same country/region with GS:SFHS, so its cohorts are likely to have a similar local genomic recombination pattern and LD structure with GS:SFHS and potentially carry alleles not common in other European cohorts, which may explain the better replication result from this group (Figure 3,s1 ).
There are, however, several limitations in the current study. Firstly, the re-adjustment strategy applied to genome-wide HRHM, whilst it reduced the computational burden, it was potentially excessively conservative in reporting true associations (observed LRT statistics were depleted from expectation, as shown in Figure 1D ), which consequently reduced the power of HRHM (50 
Conclusion
The present study showed the first application of genome-wide HRHM to a psychiatric disorder. A genome-wide significant region was identified by HRHM and the contributing genetic effect was localized to variants and haplotypes within the block. The results were partly replicated in two independent samples. Functional prediction and cis-eQTL analyses suggested that the genotype of associated-variants within the block stratified the gene expression of a potentially functional LncRNA RP1-269M15.3 and gene TOX2 in MDD-relevant brain tissues, which should be explored in further studies.
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